🇺🇸 FDA
Pipeline program

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

9140

Phase 1 mab active

Quick answer

CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine for HER2 Negative Breast Carcinoma is a Phase 1 program (mab) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
HER2 Negative Breast Carcinoma
Phase
Phase 1
Modality
mab
Status
active

Clinical trials